NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date and time:** Tuesday 5 October 2021, 9.30am

**Location:** Zoom video conference

# Committee members present

1. Dr Jane Adam [Chair] Present for all items (Chair for item 1 to 3, committee member for item 4
2. Dr Brian Shine [Vice Chair] Present for all items (Chair for item 4)
3. Professor Abdallah Al-Mohammad Present for all items
4. Dr Andrew Champion Present for all items
5. Dr Craig Buckley Present for all items
6. Dr David Maudgill Present for all items
7. Dominic Pivonka Present for all items
8. Dr Fiona MacPherson Smith Present for all items
9. Professor G.J. Melendez-Torres Present for all items
10. Hugo Pedder Present for all items
11. Dr Justin Daniels Present for items 1 to 3
12. Dr Michael Holmes Present for all items
13. Min Ven Teo Present for all items
14. Dr Peter Baker-Gulliver Present for all items
15. Richard Ballerand Present for all items
16. Dr Rita Faria Present for all items
17. Dr Steve Edwards Present for items 1 to 3 as a committee member and item 4 as an ERG representative
18. Dr Sumithra Maheswaran Present for items 1 to 3
19. Dr Roger Whittaker Present for all items

# NICE staff present:

Henry Edwards, associate director Present for items 1 to 3

Janet Robertson, associate director Present for items 4 to 5

Shonagh D’Sylva, project manager Present for items 1 to 3

Thomas Feist, project manager Present for items 4 to 5

Ewa Rupniewska, HTA adviser Present for items 1 to 3

Lorna Dunning, HTA adviser Present for item 4

Sarah Wilkes, HTA adviser Present for items 1 to 3

Sana Khan, HTA adviser Present for item 4

Adam Storrow, business analyst Present for all items

Olivia Havercroft, senior medical editor Present for items 1 to 3

Hayley Garnett, senior medical editor Present for all items

Catrin Austin, technical analyst Present for all items

Emily Eaton Turner, technical analyst Present for items 1 to 3

Claire Hawksworth, technical analyst Present for items 1 to 3

Ella Livingstone, technical adviser Present for item 4

Stephen Norton, technical analyst Present for item 4

Laura Marsden, public Involvement adviser Present for all items

Rosalee Mason, coordinator Present for all items

James Devine, coordinator Present for all items

Gemma Smith, coordinator Present for all items

Lucy Ingram, administrator Present for items 1 to 3

Sophie McHugh, administrator Present for all items

Marcia Miller, administrator Present for item 4 to 5

Daniel Greenwood, assistant Administrator Present for all items

# External review group representatives present:

Joanne Lord, Southampton health technology assessment centre Present for items 1 to 3

David Scott, Southampton health technology assessment centre Present for items 1 to 3

Tracey Jhita, BMJ Group Present for item 4

Charlotte Karner, BMJ Group Present for item 4

# Clinical & patient experts present:

Holly Heath, Patient expert   
nominated by Breast Cancer Now Present for item 1 to 3

Dr Sheeba Irshad, Senior clinical,   
lecturer in medical oncology,   
nominated by NCRI-ACP-RCP-RCR Present for item 1 to 3

Vicki McGinn, Patient expert,   
nominated by Breast Cancer Now Present for item 1 to 3

Dr Alicia Okines, Clinical expert,   
consultant medical oncologist, nominated by Seagen Present for item 1 to 3

Professor Jonathan Ledermann, Clinical expert,   
professor of medical oncology, nominated by GSK Present for item 4

Professor Peter Clark, CDF Lead Present for item 4

Rachel Downing, Patient expert,   
nominated by Target Ovarian Cancer Present for item 4

1. Introduction to the meeting
   1. The chair welcomed members of the committee and other attendees present to the meeting.
2. News and announcements
   1. None.
3. Evaluation of Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]
   1. Part 1 – Open session
      1. The chair welcomed the invited clinical and patient experts, external group representatives, members of the public and company representatives from insert company name.
      2. The chair asked all committee members, clinical and patient experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

* Dr Alicia Okines declared the following direct financial interests: She has received a speaker fee and was compensated for work on an advisory board panel for Seagen, has participated in an advisory board for Roche and AstraZeneca and Daiichi Sankyo. Her institution received research funding from Pfizer and Roche, and she received travel support to attend ESMO 2019 from Leo Pharmaceuticals. Received speaker’s fees from Pfizer, Lilly and AstraZeneca, and registration for ASCO 2021 and ESMO 2021 was received from Lilly.
  + 1. The Chair then introduced the lead team Roger Whittaker (clinical lead), Rita Faria (cost lead), and Richard Ballerand (lay advisor) who gave presentations on the clinical effectiveness and cost effectiveness of tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]
    2. The Chair also welcomed input from the patient and clinical experts during this presentation to provide further information on the clinical effectiveness of tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]
  1. Part 2 – Closed session [company representatives, clinical and patient experts, external group representatives and members of the public were asked to leave the meeting]
     1. The committee then agreed on the content of the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD]. The committee decision was reached by consensus..
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD]

A document summarising the recommendations and committee’s considerations will be available here:

https://www.nice.org.uk/guidance/indevelopment/gid-ta10708/documents

1. Appraisal of Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer - CDF review TA528 [ID1644]
   1. Part 1 – Open session
      1. The chair welcomed the invited clinical and patient experts, external group representatives, members of the public and company representatives from GlaxoSmithKline
      2. The chair asked all committee members, clinical and patient experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

* Dr Steve Edwards did not declare a specific interest, but was not a participating committee member for this topic as he was an ERG representative for this topic
* Nominated patient expert Rachel Downing declared indirect interests as her employer, Target Ovarian Cancer, has received funding from GSK In May 2020 for the nurse-led support line as part of Its response to the coronavirus pandemic. They also received funding In August 2020 from AstraZeneca for the running of Target Ovarian Cancer’s nurse-led support line and online support to women as part of the response to the coronavirus pandemic. Rachel declared a direct financial interest as she received an honorarium for a speaking engagement from GSK.
* It was agreed that her declarations would not prevent Rachel from providing expert advice to the committee
* Nominated clinical expert Professor Jonathan Ledermann declared direct financial Interests as he has previously received advisory board and lecture fees from Neopharma, GSK, AstraZeneca, Clovis Oncology, Eisai, MSD, Artios Pharma, Regeneron, VBL Therapeutics and PfIzer. His university has received research grants from AstraZeneca and MSD. He was the clinical investigator on trials with niraparib, olaparib and rucaparib in recurrent ovarian cancer and he is also editor of Gynaecological Cancer Track, ESMO Clinical Practice Guidelines and Vice President of ESGO.
* It was agreed that his declarations would not prevent Professor Ledermann from providing expert advice to the committee.
  + 1. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document [ACD] received from consultees, commentators and through the NICE website.
  1. Part 2 – Closed session [company representatives, clinical and patient experts, external group representatives and members of the public were asked to leave the meeting].
     1. The committee then agreed on the content of the Appraisal Consultation Document [ACD]. The committee decision was reached by consensus..
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD]

A document summarising the recommendations and committee’s considerations will be available here:

https://www.nice.org.uk/guidance/indevelopment/gid-ta10782/documents

1. Date of the next meeting

The next meeting of the Technology Appraisal (Committee A) will be held on Tuesday 2 November 2021 and will start promptly at 09:30am.